From 2015 to 2018, the overall cancer death rate in the United States fell by 2.3% per year for men and 2.1% per year for women—an unprecedented drop, led by accelerated decline in deaths from lung cancer and melanoma.
Theresa W. Gillespie was named associate director for community outreach and engagement at Winship Cancer Institute of Emory University.
Ajay Maker was named chief of the new Division of Surgical Oncology in the Department of Surgery and the Maurice Galante Distinguished Professorship in Surgical Oncology at the University of California, San Francisco.
Peter Abdelmessieh has joined Fox Chase Cancer Center in the Department of Bone Marrow Transplant and Cellular Therapies.
Registration has begun for the American Society for Radiation Oncology’s annual meeting, which will return to an in-person conference at McCormick Place West in Chicago, Oct. 24-27.
GE Healthcare and Sophia Geneticshave signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each patient’s genomic profile and cancer type, helping to ensure the most effective and personalized treatment.
St. Jude Children’s Research Hospital scientists have created a registry, Molecular Analysis of Childhood MELanocytic Tumors (MACMEL), to better understand pediatric melanoma.
Findings from the health outcomes group at Fred Hutchinson Cancer Research Center show that more Medicaid patients with cancer died at home without hospice care during the COVID-19 pandemic.
Merck said it will withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Keytruda has received an expanded label approval from FDA as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
